Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, 475000, Henan Province, China.
Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, 475000, Henan Province, China.
Biomed Pharmacother. 2018 Jul;103:1727-1732. doi: 10.1016/j.biopha.2018.04.094.
Increasing evidence showed that long non-coding RNAs (lncRNAs) play critical roles in tumor progression. FEZF1-AS1 is a cancer-associated lncRNA which upregulated and associated with poor prognosis in patients with cancer. However, the roles of FEZF1-AS1 in multiple myeloma (MM) remains unclear. In the present study, our data revealed that FEZF1-AS1 expression was increased both in MM samples and cell lines. Loss of functional assays indicated that FEZF1-AS1 suppression inhibited MM cells proliferation, arrested cell cycle in G0/G1 phase and induced cell apoptosis in vitro. Furthermore, our data indicated that FEZF1-AS1 functioned as a competing endogenous RNA in MM cells that regulated miR-610 expression, which suppressed Akt3. Those data showed that FEZF1-AS1 promoted MM cells proliferation through regulating miR-610/Akt3 axis, suggesting FEZF1-AS1 could be served as a potential target for cancer therapeutics in MM.
越来越多的证据表明，长非编码 RNA（lncRNA）在肿瘤进展中发挥着关键作用。FEZF1-AS1 是一种与癌症相关的 lncRNA，其在癌症患者中上调，并与预后不良相关。然而，FEZF1-AS1 在多发性骨髓瘤（MM）中的作用尚不清楚。在本研究中，我们的数据显示 FEZF1-AS1 在 MM 样本和细胞系中均表达增加。功能丧失实验表明，FEZF1-AS1 的抑制抑制了 MM 细胞的增殖，使细胞周期在 G0/G1 期停滞，并在体外诱导细胞凋亡。此外，我们的数据表明，FEZF1-AS1 在 MM 细胞中作为一种竞争性内源性 RNA 发挥作用，调节 miR-610 的表达，从而抑制 Akt3。这些数据表明，FEZF1-AS1 通过调节 miR-610/Akt3 轴促进 MM 细胞的增殖，提示 FEZF1-AS1 可以作为 MM 癌症治疗的潜在靶点。
Zotero 插件